Mavatar Launches Closed BETA of Mavatar Discovery – A New Platform for Data-Driven Precision Medicine
Stockholm, April 22, 2025 – Mavatar, a Swedish company specializing in AI- and data-driven solutions for precision medicine, today announced the launch of the closed BETA version of its first commercial platform: Mavatar Discovery. The platform is designed to help researchers, pharmaceutical companies, and biotech firms more rapidly understand the biological mechanisms of disease, identify novel biomarkers, and accelerate drug development.
Mavatar Launches Closed BETA of Mavatar Discovery – A New Platform for Data-Driven Precision Medicine
Stockholm, April 22, 2025 – Mavatar, a Swedish company specializing in AI- and data-driven solutions for precision medicine, today announced the launch of the closed BETA version of its first commercial platform: Mavatar Discovery. The platform is designed to help researchers, pharmaceutical companies, and biotech firms more rapidly understand the biological mechanisms of disease, identify novel biomarkers, and accelerate drug development.
Mavatar Discovery is built on Mavatar’s proprietary Deep Integrated Network Analysis (DINA) technology — a framework that integrates and analyzes vast amounts of biomedical data from multiple sources. The result is actionable, context-rich insights that can be directly applied in research and development.
The closed BETA period runs from April 23 to May 16, 2025, during which a selected group of users from research, pharma, and academia will gain exclusive access to the platform. The goal is to gather valuable feedback ahead of the full commercial launch planned for September 2025.
“We’ve harnessed insights from over 20 years of research to create an intuitive, cloud-based platform that delivers in minutes what used to take months,” said Johan Juhlin, CEO and Co-Founder of Mavatar.
“The BETA launch is an important milestone, and we’re excited to see how our first users experience the platform’s capabilities.”
Examples of what Mavatar Discovery enables users to do:
• Identify novel biomarkers and potential drug targets
• Explore disease biology across tissues and conditions
• Compare complex gene interactions and biological networks
• Visualize data through interactive networks and heatmaps
• Access structured, curated multi-omics datasets — no coding required
“By lowering the barrier to advanced analysis, researchers can focus on what really matters — improving precision and accelerating the path to the right treatment,” Juhlin concludes.
Linda Wakeham
Chief Marketing & Communications Officer
linda.wakeham@mavatar.com
Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden], Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.
The Company has partnerships with leading pharmaceutical companies, universities, and hospital systems. These collaborations focus on biobank studies and clinical trials, enabling research scientists to select the best drug candidates, suggest new uses for existing drugs, uncover new therapeutic targets, refine mechanisms of action, and match patients to innovative treatment options through point-of-care decision tools. Mavatar.com
Tags:
